Cardio Diagnostics Holdings, Inc. (CDIO)Stock Price & Financial Statements
AboutCardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.Show more
- Revenue $35K +104.5%
- EBITDA -$8M -13.4%
- Net Income -$8M
- EPS (Diluted) -9.30 +53.0%
- Gross Margin 100%
- EBITDA Margin -23185.82% +44.5%
- Operating Margin -23977.86% +43.5%
- Net Margin -24028.24% +51.1%
- ROE -133.96% +41.9%
- ROIC -222.66% +18.7%
- Debt/Equity 0.10 -76.2%
- Interest Coverage -448.81 -41636.6%
Key Insights
Based on financial data analysisStrengths
- ✓Momentum leader: RS Rating 92 (top 8%)
Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 14.8x book value
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y238.32%
TTM-55.78%
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM20.61%
EPS CAGR
10Y-
5Y-
3Y-
TTM-40.17%
ROCE
10Y Avg-318.86%
5Y Avg-318.86%
3Y Avg-158.4%
Latest-122.98%
Peer Comparison
Diagnostics and Omics Tools| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 VCYTVeracyte, Inc. | 2.88B | 36.27 | 44.23 | 16.01% | 12.83% | 5.07% | 4.4% | 0.03 |
 ASBPWAspire Biopharma Holdings, Inc. | 178.9K | 0.02 | -0.01 | -16351.77% | ||||
 VRAXVirax Biolabs Group Limited | 1.55M | 0.21 | -0.11 | -95.95% | -78.62% | -234.24% | 0.07 | |
CDIOCardio Diagnostics Holdings, Inc. | 141.46M | 5.26 | -0.57 | 104.45% | -415.16% | -80.38% | 0.10 | |
 AIMDAinos, Inc. | 7.24M | 1.51 | -0.97 | -83.02% | -132.32% | -148.9% | 0.77 | |
 IMDXInsight Molecular Diagnostics Inc. | 95.47M | 5.47 | -1.17 | 25.15% | -13.81% | -14.81% | ||
 SEERSeer, Inc. | 103.2M | 1.85 | -1.33 | -8.13% | -486.02% | -29.19% | 0.08 | |
 ASBPAspire Biopharma Holdings, Inc. | 62.88M | 1.32 | -5.08 | -16351.99% |
Compare CDIO vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Sales/Revenue | 0 | 901 | 950 | 17.07K | 34.89K |
| Revenue Growth % | - | - | 5.44% | 1696.32% | 104.45% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 901 | 950 | 17.07K | 34.89K |
| Gross Margin % | - | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | - | 5.44% | 1696.32% | 104.45% |
| Operating Expenses | 609.16K | 621.35K | 4.55M | 7.26M | 8.4M |
| OpEx % of Revenue | - | 68962.15% | 478884.32% | 42540.43% | 24077.86% |
| Selling, General & Admin | 597K | 573.88K | 4.49M | 7.1M | 8.35M |
| SG&A % of Revenue | - | 63693.78% | 472942.42% | 41577.26% | 23937.82% |
| Research & Development | 1.5K | 31.47K | 40.45K | 145.18K | 29.13K |
| R&D % of Revenue | - | 3492.56% | 4257.68% | 850.76% | 83.48% |
| Other Operating Expenses | 10.67K | 16K | 16K | 19.18K | 19.74K |
| Operating Income | -609.16K | -620.45K | -4.55M | -7.24M | -8.37M |
| Operating Margin % | - | -68862.15% | -478784.32% | -42440.43% | -23977.86% |
| Operating Income Growth % | - | -1.85% | -633.09% | -59.23% | -15.51% |
| EBITDA | -598.5K | -604.45K | -4.53M | -7.13M | -8.09M |
| EBITDA Margin % | - | -67086.35% | -477100.11% | -41786.34% | -23185.82% |
| EBITDA Growth % | - | -0.99% | -649.85% | -57.33% | -13.44% |
| D&A (Non-Cash Add-back) | 10.67K | 16K | 16K | 111.62K | 276.35K |
| EBIT | -609.16K | -620.45K | -4.66M | -1.64M | -8.36M |
| Net Interest Income | 0 | 0 | 0 | -6.73M | -17.58K |
| Interest Income | 0 | 0 | 0 | 1.07K | 1.06K |
| Interest Expense | 0 | 0 | 0 | 6.74M | 18.64K |
| Other Income/Expense | 4K | 0 | -112.53K | -1.13M | -17.58K |
| Pretax Income | -605.16K | -620.45K | -4.66M | -8.38M | -8.38M |
| Pretax Margin % | - | -68862.15% | -490630% | -49087.81% | -24028.24% |
| Income Tax | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 100% | 100% | 100% | 100% | 100% |
| Net Income | -605.16K | -620.45K | -4.66M | -8.38M | -8.38M |
| Net Margin % | - | -68862.15% | -490630% | -49087.81% | -24028.24% |
| Net Income Growth % | - | -2.53% | -651.23% | -79.72% | -0.08% |
| Net Income (Continuing) | -605.16K | -620.45K | -4.66M | -8.38M | -8.38M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.06 | -1.96 | -45.30 | -19.80 | -9.30 |
| EPS Growth % | - | -2981.76% | -2211.22% | 56.29% | 53.03% |
| EPS (Basic) | -0.06 | -1.96 | -45.30 | -19.80 | -9.30 |
| Diluted Shares Outstanding | 9.52M | 317.16K | 3.09M | 422.84K | 26.89M |
| Basic Shares Outstanding | 9.52M | 317.16K | 3.09M | 422.84K | 26.89M |
| Dividend Payout Ratio | - | - | - | - | - |
Balance Sheet
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Total Current Assets | 245.92K | 803.51K | 5.89M | 2.77M | 8.79M |
| Cash & Short-Term Investments | 237.09K | 512.77K | 4.12M | 1.28M | 7.83M |
| Cash Only | 237.09K | 512.77K | 4.12M | 1.28M | 7.83M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 901 | 0 | 4.96K | 18.61K |
| Days Sales Outstanding | - | 365 | - | 106.09 | 194.71 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 0 | 250K | 0 | 1.48M | 621.32K |
| Total Non-Current Assets | 200.46K | 298.49K | 363.59K | 1.7M | 1.82M |
| Property, Plant & Equipment | 0 | 0 | 0 | 1.15M | 1.11M |
| Fixed Asset Turnover | - | - | - | 0.01x | 0.03x |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 200.46K | 298.49K | 358.64K | 536.74K | 706.42K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 4.95K | 12.85K | 12.85K |
| Total Assets | 446.38K | 1.1M | 6.25M | 4.46M | 10.62M |
| Asset Turnover | - | 0.00x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | - | 146.88% | 467.11% | -28.6% | 137.89% |
| Total Current Liabilities | 386.01K | 33.88K | 1.95M | 841.14K | 631.7K |
| Accounts Payable | 39.54K | 33.88K | 1.1M | 243.21K | 87.66K |
| Days Payables Outstanding | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 849.03K | 374K | 306.76K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 346.47K | 0 | 0 | 0 | 0 |
| Current Ratio | 0.64x | 23.71x | 3.02x | 3.29x | 13.92x |
| Quick Ratio | 0.64x | 23.71x | 3.02x | 3.29x | 13.92x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 663.1K | 425.83K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 663.1K | 425.83K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 386.01K | 33.88K | 1.95M | 1.5M | 1.06M |
| Total Debt | 0 | 0 | 849.03K | 1.26M | 969.86K |
| Net Debt | -237.09K | -512.77K | -3.27M | -22.5K | -6.86M |
| Debt / Equity | - | - | 0.20x | 0.43x | 0.10x |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | - | - | - | -1.08x | -448.81x |
| Total Equity | 60.37K | 1.07M | 4.3M | 2.96M | 9.56M |
| Equity Growth % | - | 1669.42% | 302.74% | -31.23% | 223.1% |
| Book Value per Share | 0.01 | 3.37 | 1.39 | 7.00 | 0.36 |
| Total Shareholders' Equity | 60.37K | 1.07M | 4.3M | 2.96M | 9.56M |
| Common Stock | 1.05K | 123 | 95 | 205 | 459 |
| Retained Earnings | -710.11K | -1.33M | -5.99M | -14.37M | -22.75M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|
| Cash from Operations | 25.86K | -585.29K | -5.09M | -5.67M | -4.99M |
| Operating CF Margin % | - | -64960.16% | -535891.37% | -33238.65% | -14310.99% |
| Operating CF Growth % | - | -2363.39% | -769.82% | -11.42% | 11.97% |
| Net Income | -605.16K | -620.45K | -4.66M | -8.38M | -8.38M |
| Depreciation & Amortization | 10.67K | 16K | 16K | 111.62K | 276.35K |
| Stock-Based Compensation | 589.26K | 60K | 0 | 1.28M | 2.59M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -3.28K | 112.53K | 1.1M | 0 |
| Working Capital Changes | 31.09K | -37.56K | -558.52K | 208.81K | 522.84K |
| Change in Receivables | 0 | -901 | 0 | -4.96K | -13.65K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 136.35K | 0 | 0 |
| Cash from Investing | -29.91K | -364.03K | -368K | -794.29K | -404.19K |
| Capital Expenditures | -29.91K | -114.03K | -76.15K | -597.01K | -214.76K |
| CapEx % of Revenue | - | 12655.83% | 8016.21% | 3498.48% | 615.55% |
| Acquisitions | 0 | -250K | 141.49K | 0 | 0 |
| Investments | - | - | - | - | - |
| Other Investing | 0 | 0 | -433.33K | -197.28K | -189.43K |
| Cash from Financing | 240K | 1.23M | 9.06M | 3.63M | 11.94M |
| Debt Issued (Net) | 0 | 0 | -188.67K | 4.5M | 0 |
| Equity Issued (Net) | 0 | 1000K | 1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 240K | 105K | -2.73M | -867.53K | -605.69K |
| Net Change in Cash | 235.95K | 275.68K | 3.6M | -2.83M | 6.54M |
| Free Cash Flow | -4.05K | -699.32K | -5.09M | -6.47M | -5.4M |
| FCF Margin % | - | -77615.98% | -535891.58% | -37893.15% | -15469.46% |
| FCF Growth % | - | -17162.9% | -627.99% | -27.02% | 16.53% |
| FCF per Share | -0.00 | -2.20 | -1.65 | -15.29 | -0.20 |
| FCF Conversion (FCF/Net Income) | -0.04x | 0.94x | 1.09x | 0.68x | 0.60x |
| Interest Paid | 0 | 0 | 0 | 30.49K | 18.64K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 |
Key Ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -1002.51% | -109.96% | -173.6% | -230.77% | -133.96% |
| Return on Invested Capital (ROIC) | - | -245.81% | -429.49% | -273.72% | -222.66% |
| Gross Margin | - | 100% | 100% | 100% | 100% |
| Net Margin | - | -68862.15% | -490630% | -49087.81% | -24028.24% |
| Debt / Equity | - | - | 0.20x | 0.43x | 0.10x |
| Interest Coverage | - | - | - | -1.08x | -448.81x |
| FCF Conversion | -0.04x | 0.94x | 1.09x | 0.68x | 0.60x |
| Revenue Growth | - | - | 5.44% | 1696.32% | 104.45% |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics